SynthesisAlzheimer's & dementia : the journal of the Alzheimer's Association2020
Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS.
Synthesis in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02372773 (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Pooled it
- Cellular signatures underlying functional resilience in presymptomatic frontotemporal dementia.Brain : a journal of neurology · 2026Article
- Hyperorality in Frontotemporal Dementia: How Psychiatric and Neural Correlates Change During the Disease Course.The Journal of neuropsychiatry and clinical neurosciences · 2026Article
- Neuropsychiatric symptoms cluster and fluctuate over time in behavioral variant frontotemporal dementia.Psychiatry and clinical neurosciences · 2025Article
- Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.Nature aging · 2025Article
- Molecular mechanisms and biomarkers in neurodegenerative disorders: a comprehensive review.Molecular biology reports · 2025Review
- Article
- Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.International journal of molecular sciences · 2024Review
- Neuropsychiatric Symptoms Cluster and Fluctuate Over Time in Behavioral Variant Frontotemporal Dementia.medRxiv : the preprint server for health sciences · 2024Article
- Differential diagnosis of frontotemporal dementia subtypes with explainable deep learning on structural MRI.Frontiers in neuroscience · 2024Article
- Single-cell RNA-seq reveals alterations in peripheral CX3CR1 and nonclassical monocytes in familial tauopathy.Genome medicine · 2023Article
- Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia.Brain : a journal of neurology · 2023Article
- Cerebrospinal fluid level of proNGF as potential diagnostic biomarker in patients with frontotemporal dementia.Frontiers in aging neuroscience · 2023Article
- New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- The contribution of behavioral features to caregiver burden in FTLD spectrum disorders.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Proposed research criteria for prodromal behavioural variant frontotemporal dementia.Brain : a journal of neurology · 2022Article
- Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.Cell reports. Medicine · 2022Article
- Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.Brain : a journal of neurology · 2022Article
- Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling.NeuroImage. Clinical · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
introductionFamilial frontotemporal lobar degeneration (f-FTLD) due to autosomal dominant mutations is an important entity for developing treatments for FTLD. The Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) longitudinal studies were designed to describe the natural history of f-FTLD.
methodsWe summarized recent publications from the ARTFL and LEFFTDS studies, along with other recent publications describing the natural history of f-FTLD.
resultsPublished and emerging studies are producing data on all phases of f-FTLD, including the asymptomatic and symptomatic phases of disease, as well as the transitional phase when symptoms are just beginning to develop. These data indicate that rates of change increase along with disease severity, which is consistent with commonly cited models of neurodegeneration, and that measurement of biomarkers may predict onset of symptoms. DISCUSSION: Data from large multisite studies are producing important data on the natural history of f-FTLD that will be critical for planning intervention trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.